- Home
- GOVX vs POAI Comparison
GOVX vs POAI Comparison
Compare GOVX & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- POAI
- Stock Information
- Founded
- GOVX 2001
- POAI 2002
- Country
- GOVX United States
- POAI United States
- Employees
- GOVX N/A
- POAI N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- POAI Industrial Specialties
- Sector
- GOVX Health Care
- POAI Health Care
- Exchange
- GOVX Nasdaq
- POAI Nasdaq
- Market Cap
- GOVX 7.6M
- POAI 8.9M
- IPO Year
- GOVX N/A
- POAI N/A
- Fundamental
- Price
- GOVX $0.75
- POAI $0.80
- Analyst Decision
- GOVX Strong Buy
- POAI Hold
- Analyst Count
- GOVX 4
- POAI 1
- Target Price
- GOVX $10.50
- POAI N/A
- AVG Volume (30 Days)
- GOVX 2.7M
- POAI 169.5K
- Earning Date
- GOVX 08-05-2025
- POAI 08-12-2025
- Dividend Yield
- GOVX N/A
- POAI N/A
- EPS Growth
- GOVX N/A
- POAI N/A
- EPS
- GOVX N/A
- POAI N/A
- Revenue
- GOVX $5,591,576.00
- POAI $1,729,269.00
- Revenue This Year
- GOVX N/A
- POAI $486.27
- Revenue Next Year
- GOVX N/A
- POAI $65.50
- P/E Ratio
- GOVX N/A
- POAI N/A
- Revenue Growth
- GOVX N/A
- POAI 24.17
- 52 Week Low
- GOVX $0.43
- POAI $0.55
- 52 Week High
- GOVX $11.18
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- GOVX 47.67
- POAI 37.42
- Support Level
- GOVX $0.60
- POAI $0.78
- Resistance Level
- GOVX $0.76
- POAI $0.82
- Average True Range (ATR)
- GOVX 0.08
- POAI 0.05
- MACD
- GOVX 0.02
- POAI 0.00
- Stochastic Oscillator
- GOVX 59.45
- POAI 49.35
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.